Establishment Labs Holdings Inc. (NASDAQ:ESTA) Given Consensus Recommendation of “Moderate Buy” by Analysts

Establishment Labs Holdings Inc. (NASDAQ:ESTA) has been assigned a consensus rating of “Moderate Buy” from the eight analysts that are covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and six have assigned a buy recommendation to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $78.1429.

ESTA has been the subject of a number of research reports. BTIG Research upped their price objective on shares of Establishment Labs from $70.00 to $81.00 and gave the stock a “buy” rating in a research note on Friday, November 14th. Mizuho raised their target price on shares of Establishment Labs from $85.00 to $90.00 and gave the company an “outperform” rating in a research report on Wednesday. Citigroup upped their price target on shares of Establishment Labs from $62.00 to $75.00 and gave the stock a “neutral” rating in a research report on Thursday, December 11th. Wall Street Zen upgraded shares of Establishment Labs from a “sell” rating to a “hold” rating in a research note on Sunday, October 19th. Finally, Canaccord Genuity Group lifted their price objective on shares of Establishment Labs from $72.00 to $85.00 and gave the company a “buy” rating in a report on Wednesday.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in ESTA. Affinity Asset Advisors LLC grew its stake in shares of Establishment Labs by 19.6% during the second quarter. Affinity Asset Advisors LLC now owns 334,863 shares of the company’s stock worth $14,302,000 after acquiring an additional 54,863 shares during the last quarter. Mudita Advisors LLP raised its position in shares of Establishment Labs by 15.6% in the 1st quarter. Mudita Advisors LLP now owns 479,359 shares of the company’s stock valued at $19,560,000 after purchasing an additional 64,859 shares during the last quarter. Milestone Asset Management LLC acquired a new stake in Establishment Labs in the 2nd quarter worth approximately $523,000. Hood River Capital Management LLC grew its position in Establishment Labs by 138.2% during the 2nd quarter. Hood River Capital Management LLC now owns 53,124 shares of the company’s stock worth $2,269,000 after purchasing an additional 30,825 shares during the last quarter. Finally, Swiss National Bank increased its stake in Establishment Labs by 1.3% during the 1st quarter. Swiss National Bank now owns 39,000 shares of the company’s stock valued at $1,591,000 after purchasing an additional 500 shares in the last quarter. 72.91% of the stock is currently owned by hedge funds and other institutional investors.

Establishment Labs Stock Up 6.9%

Shares of NASDAQ:ESTA opened at $74.42 on Friday. The business’s 50 day moving average is $61.71 and its 200 day moving average is $47.73. The stock has a market cap of $2.16 billion, a P/E ratio of -26.20 and a beta of 1.01. Establishment Labs has a 52-week low of $26.56 and a 52-week high of $78.24. The company has a quick ratio of 2.10, a current ratio of 3.33 and a debt-to-equity ratio of 15.06.

Establishment Labs (NASDAQ:ESTA) last issued its earnings results on Wednesday, November 5th. The company reported ($0.38) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.16. Establishment Labs had a negative return on equity of 235.45% and a negative net margin of 43.45%.The business had revenue of $53.78 million during the quarter, compared to analyst estimates of $52.28 million. During the same period in the previous year, the company posted ($0.59) EPS. Establishment Labs’s revenue was up 33.8% on a year-over-year basis. Sell-side analysts predict that Establishment Labs will post -2.41 EPS for the current year.

About Establishment Labs

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.